Navigation Links
Amgen and Peregrine Under StockCall Scrutiny: Pharma Stocks Deal with Drug Developments and Patents
Date:2/6/2013

LONDON, February 6, 2013 /PRNewswire/ --

Pharma stocks performed fairly well lately. However, the main concern for all the major companies was related to the patent expiry of their blockbuster drugs. Amgen Inc. (NASDAQ: AMGN) is about to lose its patent exclusivity for its cancer drug Neupogen. However, the sector is also witnessing good merger and acquisition activities, where big players are acquiring smaller companies in order to make up the losses sustained through patent expirations. Smaller biotech companies are also betting big on developing drugs for various cancers, though the prospects do not look so bright. StockCall analysts have released their latest round of technical research on Amgen and Peregrine. This free research can be accessed by signing up now at

http://www.stockcall.com/registration

Amgen Provides Optimistic Projections

Amgen recently reported positive results for the fourth quarter. Its revenue grew 11.25 percent to $4.42 billion while its adjusted net income stood at $1.40 per share, beating consensus estimate of $1.39 per share in quarterly net income. Amgen expects its FY 2013 adjusted earnings to be in the range of $6.85 and $7.15 per share, while revenue is likely to be in the range of $17.8 billion and $18.2 billion, in comparison to $17.3 billion in revenue it earned for FY2012. Thus, while the company is likely to report better results, but the rate of growth is likely to be a little muted. However, Amgen surpassed consensus estimates for the projections. Register today and read our free technical report on Amgen at

http://www.StockCall.com/AMGN020613.pdf

The company also successfully conducted phase 3 of its cancer drug Neulasta. Amgen draws a big chunk of its revenue from Neupogen franchise. However, the drug would go off patent protection by the end of 2013 and the loss of exclusivity is expected to affect Amgen. Neupogen faces stiff competition from the companies like Novartis in the markets outside of the U.S. and these competing companies may launch their products in the U.S., causing further damage. However, the company has somewhat strong drug candidates including AMG145, a cholesterol drug candidate.

Amgen stock grew over 25 percent in the past 12 months. It also offers good dividend yield of 2.17 percent. The company is likely to increase its dividend in the future, thus offering good returns to the investors. Amgen is also growing through acquisitions as it recently completed the purchase of Icelandic company decode Genetics.

Peregrine Struggles with Cancer Drug Development

Peregrine Pharmaceuticals Inc. specializes in developing therapies for viral infections. It also develops treatments for cancers. It is currently engaged in developing treatment for non-small cell lung cancer. If successful, the company will make big fortunes as non-small cell lung cancer accounts for about 80 percent of lung cancer cases. However, the company does not have very solid track record. The drug candidate bavituximab has been controversial as it led to the stock's massive tumble in September 2012. Sign up to download the free technical analysis on Peregrine Pharmaceuticals at

http://www.StockCall.com/PPHM020613.pdf  

Peregrine is a small company with the market capitalization of less than $300 million. The stock is quite volatile as well. The company is currently looking to get past the phase II for bavituximab. Overall, the stock may be held if it is already in your portfolio. On the upside, the stock is currently trading about 50 percent below its 52-week high, thus in case of positive news on its lung cancer drug, Peregrine stock has massive upside.

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at

http://www.stockcall.com


'/>"/>
SOURCE StockCall.com
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
2. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
3. Amgen to Present at the Baird Growth Stock Conference
4. Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
5. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
6. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
7. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
8. Amgen Completes Acquisition of KAI Pharmaceuticals
9. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
10. Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
11. Amgen To Present At The Baird Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... Feb. 5, 2016 Aethlon Medical, Inc. (Nasdaq: ... and CEO, will be presenting at Source Capital Group,s 2016 ... NY at 2:15 p.m. ET on Wednesday, February ... Panel discussion taking place at 3:15 p.m. ET. ... one hour after the conclusion of the live event. The ...
(Date:2/5/2016)... , Feb. 5, 2016 Dehaier ... Medical" or the "Company"), which develops, markets and ... in China and international ... plan which aims to concentrate the Company,s resources ... sleep respiratory business and to focus more on ...
(Date:2/5/2016)...  Henry Schein, Inc. (NASDAQ: HSIC ), the world,s ... office-based dental, animal health and medical practitioners, announced today ... a majority ownership interest in Dental Cremer S.A., a ... Brazil . --> ... the dental distribution business of Cremer S.A. With 2015 ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... , ... Health and wellness is a topic that should concern all Americans; ... experiencing an illness. Migraines are a severe form of a headache and often are ... wish the pain on their worst enemy, the feeling can last for many hours ...
(Date:2/5/2016)... NJ (PRWEB) , ... February 05, 2016 , ... ... Primary Care for Patients with Rare Diseases, a continuing medical education (CME) event ... is the first of its kind—and a first for ACCORD, whose mission is ...
(Date:2/5/2016)... ... February 05, 2016 , ... KICVentures ( ... Career Development event in New York City on Thursday, January 21, 2016. ... of Mediacom, (both alumnus of the varsity Columbia soccer program) spoke at the ...
(Date:2/5/2016)... ... , ... Susan Polk Health Insurance Company recently released a report ... in 2016. To view the report, see below, or visit Susan Polk's blog. ... Obispo seniors who rely on Medicare health insurance and whose monthly income includes social ...
(Date:2/4/2016)... ... February 04, 2016 , ... Dr. Carol Francis ... on February 19-21, 2016, in Southern California . The International Hypnosis Federation 2016 ... 30 professional speakers, including Clinical Psychologist and Hypnotherapist Dr. Carol Francis ...
Breaking Medicine News(10 mins):